AstraZeneca
FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
Published in Medical Letter on the CDC and FDA, December 30th, 2007
AstraZeneca (NYSE:AZN) agrees with the FDA conclusion which states "FDA continues to conclude that long-term use of these drugs is not likely to be associated with an increased risk of heart problems. FDA recommends that health care providers continue to prescribe, and patients continue to use, these products as described in the labeling for the two drugs." AstraZeneca also supports the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Heart Failure
Another 'smart' cancer drug can have toxic effects on the heart - Breast Cancer
Research on breast cancer detailed by M.L. Krychman and co-authors - Cancer
Amgen in Discussions with FDA to Update U.S. Prescribing Information for ESAs - Cancer Vaccines
AVAX Technologies Announces Successful Completion of Phase I / II Study of MVax(R) in Patients with Stage 3 and 4 Melanoma - Clinical Trial Research
Studies from D.F. Kripke et al have provided new data on clinical trial research - Cystic Fibrosis
Study data from E. Bates and co-authors update knowledge of cystic fibrosis - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
